Myriad Genetics Crescita futura

Future criteri di controllo 0/6

Myriad Genetics prevede che gli utili e i ricavi cresceranno rispettivamente di 60.5% e 7.2% all'anno. Si prevede che l'EPS crescerà di 61.4% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 4.4% in 3 anni.

Informazioni chiave

60.5%

Tasso di crescita degli utili

61.4%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.3%
Tasso di crescita dei ricavi	7.2%
Rendimento futuro del capitale proprio	4.4%
Copertura analitica	Good
Ultimo aggiornamento	18 Nov 2024

Aggiornamenti recenti sulla crescita futura

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 13

Recent updates

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 13

Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Nov 02

Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Nov 02

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 11

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

May 09

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Mar 28

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Feb 02

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Jan 31

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Dec 18

Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Aug 07

Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Apr 13

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:MYGN - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	975	-12	24	48	10
12/31/2025	888	-65	9	33	14
12/31/2024	841	-104	3	6	14
9/30/2024	824	-116	-107	-70	N/A
6/30/2024	802	-155	-141	-93	N/A
3/31/2024	774	-235	-155	-96	N/A
12/31/2023	753	-263	-184	-111	N/A
9/30/2023	734	-274	-138	-63	N/A
6/30/2023	699	-248	-119	-44	N/A
3/31/2023	695	-146	-155	-93	N/A
12/31/2022	678	-112	-152	-106	N/A
9/30/2022	661	-77	-143	-108	N/A
6/30/2022	672	-18	-164	-145	N/A
3/31/2022	682	-8	-117	-100	N/A
12/31/2021	691	-27	1	19	N/A
9/30/2021	684	-57	-7	14	N/A
6/30/2021	662	-97	-26	-6	N/A
3/31/2021	566	-148	11	28	N/A
12/31/2020	557	-224	-40	-27	N/A
9/30/2020	598	-194	-25	-14	N/A
6/30/2020	639	-199	51	61	N/A
3/31/2020	761	-148	53	62	N/A
12/31/2019	813	-26	43	52	N/A
9/30/2019	835	-15	83	92	N/A
6/30/2019	851	5	75	84	N/A
3/31/2019	830	23	91	100	N/A
12/31/2018	796	26	96	105	N/A
9/30/2018	767	54	92	100	N/A
6/30/2018	744	133	N/A	116	N/A
3/31/2018	749	130	N/A	105	N/A
12/31/2017	763	126	N/A	134	N/A
9/30/2017	771	101	N/A	133	N/A
6/30/2017	729	17	N/A	106	N/A
3/31/2017	757	32	N/A	108	N/A
12/31/2016	751	63	N/A	113	N/A
9/30/2016	748	94	N/A	134	N/A
6/30/2016	741	117	N/A	166	N/A
3/31/2016	757	121	N/A	179	N/A
12/31/2015	747	108	N/A	163	N/A
9/30/2015	738	95	N/A	163	N/A
6/30/2015	723	80	N/A	141	N/A
3/31/2015	722	95	N/A	130	N/A
12/31/2014	725	110	N/A	112	N/A
9/30/2014	745	137	N/A	107	N/A
6/30/2014	778	176	N/A	190	N/A
3/31/2014	764	187	N/A	212	N/A
12/31/2013	737	188	N/A	238	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che MYGN rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che MYGN rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che MYGN rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di MYGN ( 7.2% all'anno) crescerà più lentamente rispetto al mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di MYGN ( 7.2% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di MYGN sarà basso tra 3 anni ( 4.4 %).

Myriad Genetics Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Price target decreased by 11% to US$26.69

Myriad Genetics, Inc. Provides Earnings Guidance for the Third Quarter 2024 and Reaffirms Earnings Guidance for the Full-Year 2024

Consensus EPS estimates fall by 25%

Price target increased by 7.6% to US$27.82

Myriad Genetics, Inc. Raises Earnings Guidance for the Full Year 2024

Recent updates

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Price target decreased by 11% to US$26.69

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Myriad Genetics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024

Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Myriad Genetics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

CEO, President & Director notifies of intention to sell stock

Now 21% undervalued after recent price drop

Myriad Genetics, Inc. Provides Earnings Guidance for the Third Quarter 2024 and Reaffirms Earnings Guidance for the Full-Year 2024

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Myriad Genetics, Inc. to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Independent Director recently sold US$271k worth of stock

Independent Director notifies of intention to sell stock

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking

Insider recently sold US$321k worth of stock

Consensus EPS estimates fall by 25%

Price target increased by 7.6% to US$27.82

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Myriad Genetics, Inc. Raises Earnings Guidance for the Full Year 2024

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer, Effective September 3, 2024

Myriad Genetics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?

New minor risk - Financial position

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

CEO, President & Director recently sold US$5.7m worth of stock

CEO, President & Director notifies of intention to sell stock

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to US$0.93 loss

Price target increased by 8.9% to US$24.50

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings: EPS misses analyst expectations

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics.

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Consensus EPS estimates fall by 21%, revenue upgraded

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Shareholder dilution

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer, Effective December 11, 2023

Myriad Genetics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 8.2% to US$21.67

Bernstein Litowitz Berger & Grossmann LLP Proposes Settlement of Class Action Involving Persons Who Purchased or Acquired Myriad Genetics, Inc. Common Stock

Insufficient new directors

Consensus EPS estimates fall by 52%

Myriad Genetics Announces Enhancements to the Genesight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2023

Myriad Genetics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Myriad Genetics, Inc. Announces Inclusion of Breast Density to Myrisk(R) with Riskscore(R) Breast Cancer Risk Assessment

Independent Director notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Adam Brufsky as Scientific Advisor

Consensus EPS estimates fall by 27%, revenue upgraded

Myriad Genetics, Inc. Revises Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind